NASDAQ: YMABY Mabs Therapeutics Inc Stock Ownership - Who owns Y Mabs Therapeutics?
Insider buying vs selling
Have Y Mabs Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Thomas Gad | CHIEF BUSINESS OFFICER | 2025-06-03 | 103,000 | $2.00 | $206.00kBuy |
| Thomas Gad | CHIEF BUSINESS OFFICER | 2025-03-07 | 10,810 | $5.23 | $56.54kSell |
| Michael J. Rossi | PRESIDENT CEO | 2025-03-07 | 3,917 | $5.20 | $20.37kSell |
| Thomas Gad | CHIEF BUSINESS OFFICER | 2024-09-19 | 22,831 | $4.38 | $100.00kBuy |
| Thomas Gad | CHIEF BUSINESS OFFICER | 2024-09-16 | 30,000 | $12.97 | $389.10kSell |
YMAB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when YMAB insiders and whales buy or sell their stock.
YMAB Shareholders
What type of owners hold Y Mabs Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Johan Wedellwedellsborg | 11.60% | 5,254,285 | $45.13M | Insider |
| Biotech Aps Wg | 10.07% | 4,559,233 | $39.16M | Insider |
| Paradigm Biocapital Advisors LP | 9.36% | 4,236,346 | $36.39M | Institution |
| Acorn Capital Advisors LLC | 7.55% | 3,418,995 | $29.37M | Institution |
| Blackrock Inc | 6.07% | 2,748,077 | $23.61M | Institution |
| Thomas Gad | 5.51% | 2,494,114 | $21.42M | Insider |
| Caligan Partners LP | 5.17% | 2,342,609 | $20.12M | Institution |
| James Healy | 4.97% | 2,250,961 | $19.34M | Insider |
| Sofinnova Investments Inc | 4.85% | 2,194,278 | $18.85M | Institution |
| Vanguard Group Inc | 4.29% | 1,943,285 | $16.69M | Institution |
YMAB vs Biotech Stocks
Y Mabs Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.